A 10 mg/mL vial requires different draw volumes than a 20 mg/mL vial or a 30 mg/mL vial
What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader
I take 2 tablespoons about 1 hour before I exercise
The technology Is safer for user and patient, less painful, offers wide application range, efficient absorption, accurate delivery and has scientifically proven efficacy with supporting case studies
At Elite Primary Care Group, IV therapy is offered for patients who can benefit from the rapid and efficient delivery of fluids, vitamins, minerals, or medications directly into the bloodstream
The policy brief argues treating obesity now for patients on Medicaid could save the state money in the long run, by avoiding future treatment for heart disease, Type 2 diabetes and other chronic conditions associated with obesity